Included patients were aged ≥18 years with a documented history of AC, a documented positive skin prick test and/or positive validated IgE test to perennial allergen (eg cat dander, dog dander, dust mites and/or cockroach) or to seasonal allergen (eg grass, ragweed, and/ or tree pollen) within 6 months before the study, or a positive skin prick test at Visit 1a and showing signs and symptoms of AC, ie tearing, itching and redness, that were likely to continue for the next weeks. The patients had to have a minimum score of 4 on a 0–10 numeric rating scale (0, no symptom; 10, very severe symptom) in at least one of three categories (ocular itching, ocular redness, and ocular tearing). The main exclusion criteria were a history of known contraindications or sensitivities to the use of the drug or any of its components; intraocular surgery or planned surgery during study participation and within 2 weeks after follow-up; ocular trauma in the 6 months before the study; clinical evidence of ocular herpes simplex or ocular herpes zoster infectious disease; or any clinically significant (CS) external ocular disease within 30 days before study start.